Asthma | Pharmacor | Pharmacor | G7 | 2015

Last Updated 21 September 2015

The asthma market has historically been one of the most lucrative drug markets in the pharmaceutical industry owing to a large and growing patient population. However, despite a robust pipeline in asthma with a substantial growth potential, generic and/or branded-generic price erosion, increased product competition, and an increasingly difficult pricing and reimbursement environment will stabilize the asthma market over the forecast period. The uptake of the first once-daily long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) fixed-dose combination (vilanterol/fluticasone furoate [GlaxoSmithKline/Theravance’s Breo/Relvar]), introduction of the first anticholinergic in asthma due to the label extension of a leading COPD agent (tiotropium [Boehringer Ingelheim’s Spriva]) to asthma, and launches of six different novel anticytokine therapies and a new class of two LABA/long-acting muscarinic antagonist (LAMA)/ICS combination therapies within the next ten years will offset the market constraints. Despite the high number of effective asthma therapies for mild to moderate asthma patients, considerable opportunity exists for the development of new agents that target the heterogeneous population of asthma patients with severe symptoms and who are resistant to LABA/ICS combination therapies. Any emerging therapy that serves even a fraction of this underserved segment of the asthma market will have considerable sales potential.

Login to access report